Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care

普拉格雷 替卡格雷 医学 急性冠脉综合征 氯吡格雷 内科学 心肌梗塞 随机对照试验 危险系数 急诊医学 置信区间
作者
Nils Krüger,Johannes Krefting,Thorsten Kessler,Raphael Schmieder,Fabian Starnecker,Alexander Dutsch,Christian Graesser,Ulrike Meyer-Lindemann,T Storz,Irina Pugach,Christian Frieß,Zhifen Chen,Dario Bongiovanni,I. Manea,Tobias Dreischulte,Frank Offenborn,P Krase,Hendrik B. Sager,Jens Wiebe,Sebastian Kufner
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (12): e2448389-e2448389 被引量:2
标识
DOI:10.1001/jamanetworkopen.2024.48389
摘要

Importance In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y12 receptor inhibitors. The ISAR-REACT5 randomized clinical trial demonstrated superiority for prasugrel, although concerns were raised about the generalizability of some underpowered subgroup analyses. Objectives To emulate a randomized clinical trial evaluating the safety and effectiveness of ticagrelor vs prasugrel under the conditions of routine care in individuals with ACS planned to undergo an invasive treatment strategy. Design, Setting, and Participants This new-user cohort study included secondary data from a German statutory health insurance claims database between January 2012 and December 2021, using 1:1 propensity score nearest-neighbor matching to emulate ISAR-REACT5. Individuals with ACS receiving either ticagrelor or prasugrel treatment after hospital discharge were followed up for 1 year. Eligibility criteria closely emulated those of ISAR-REACT5 and included age of 18 years or older and cardiovascular risk factors. Data were analyzed from May 2023 to May 2024. Exposure Outpatient prescription of ticagrelor or prasugrel. Main Outcomes and Measures The primary end point was the composite of all-cause mortality, myocardial infarction (MI), or stroke within 1 year of outpatient treatment initiation. Secondary end points included individual components of the primary end point and stent thrombosis. The safety end point was major bleeding. A Cox proportional hazards regression model was fitted to the overall cohort. Results Of 17 642 propensity score–matched individuals (mean [SD] age, 63.1 [10.9] years; 73.9% male), 8821 received ticagrelor and 8821 received prasugrel. Agreement was met in 11 of 12 predefined agreement metrics when comparing the results with ISAR-REACT5. The primary composite end point of all-cause mortality, MI, or stroke occurred in 815 individuals (9.2%) receiving ticagrelor and 663 (7.5%) receiving prasugrel (hazard ratio [HR], 1.24; 95% CI, 1.12-1.37). Myocardial infarction (HR, 1.20; 95% CI, 1.06-1.36) and stroke (HR, 1.33; 95% CI, 1.02-1.74) each occurred significantly more often in the ticagrelor group. Analysis of all-cause mortality (HR, 1.27; 95% CI, 0.99-1.64), stent thrombosis (HR, 1.11; 95% CI, 0.89-1.30), and major bleeding (HR, 1.12; 95% CI, 0.96-1.32) revealed no significant differences between treatment groups. Subgroup analysis showed that prasugrel was associated with the primary composite end point in fewer individuals with ST-segment elevation MI (338 of 4941 [6.8%] vs 451 of 4852 [9.3%]). Conclusions and Relevance This cohort study found that prasugrel was associated with lower rates of all-cause mortality, MI, or stroke compared with ticagrelor in individuals with ACS undergoing an invasive treatment strategy in routine care, particularly in individuals with ST-segment elevation MI. The findings suggest that carefully designed database studies can complement and extend findings from randomized clinical trials, informing guidelines and clinical decision-making.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生动毛衣发布了新的文献求助10
1秒前
阿狸a完成签到,获得积分10
1秒前
化工兔发布了新的文献求助10
1秒前
哦莫完成签到 ,获得积分10
1秒前
123完成签到,获得积分10
1秒前
connieGZ完成签到,获得积分10
1秒前
英俊的铭的应助被能干的尔竹采纳,获得10
1秒前
黑芝麻汤圆55完成签到,获得积分10
1秒前
打打的应助被丿沨采纳,获得10
1秒前
Cyoung完成签到,获得积分10
2秒前
123完成签到,获得积分10
2秒前
碧蓝丹烟完成签到,获得积分10
3秒前
文艺的老姆完成签到,获得积分10
3秒前
细心的安雁完成签到,获得积分10
4秒前
柒夏完成签到,获得积分10
4秒前
4秒前
5秒前
团子完成签到,获得积分10
5秒前
苹果绝悟完成签到 ,获得积分10
6秒前
guoqing完成签到 ,获得积分10
7秒前
iamcrazyboy完成签到,获得积分10
7秒前
LLLLXR完成签到,获得积分10
7秒前
南瓜小笨111111完成签到 ,获得积分10
8秒前
wdlc完成签到,获得积分10
8秒前
8秒前
朝颜完成签到,获得积分10
9秒前
Seth完成签到,获得积分0
9秒前
Ftplanet完成签到,获得积分10
9秒前
现实的秋凌完成签到,获得积分10
9秒前
欢喜可愁完成签到 ,获得积分10
10秒前
伶俐剑通完成签到 ,获得积分10
10秒前
10秒前
赘婿的应助被黑芝麻汤圆55采纳,获得10
11秒前
所所的应助被小马猪采纳,获得10
11秒前
源源完成签到,获得积分10
12秒前
小七完成签到,获得积分10
12秒前
123发布了新的文献求助10
13秒前
卷卷完成签到,获得积分10
13秒前
cwzjy0457完成签到,获得积分10
13秒前
林大侠完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808